Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer
Creators: name: Fendler, Annika
name: Shepherd, Scott TC
name: Au, Lewis
name: Wu, Mary
name: Harvey, Ruth
name: Wilkinson, Katalin A
name: Schmitt, Andreas M
name: Tippu, Zayd
name: Shum, Benjamin
name: Farag, Sheima
name: Rogiers, Aljosja
name: Carlyle, Eleanor
name: Edmonds, Kim
name: Del Rosario, Lyra
name: Lingard, Karla
name: Mangwende, Mary
name: Holt, Lucy
name: Ahmod, Hamid
name: Korteweg, Justine
name: Foley, Tara
name: Barber, Taja
name: Emslie-Henry, Andrea
name: Caulfield-Lynch, Niamh
name: Byrne, Fiona
name: Deng, Daqi
name: Kjaer, Svend
name: Song, Ok-Ryul
name: Queval, Christophe J
name: Kavanagh, Caitlin
name: Wall, Emma C
name: Carr, Edward J
name: Caidan, Simon
name: Gavrielides, Mike
name: MacRae, James I
name: Kelly, Gavin
name: Peat, Kema
name: Kelly, Denise
name: Murra, Aida
name: Kelly, Kayleigh
name: O’Flaherty, Molly
name: Shea, Robyn L
name: Gardner, Gail
name: Murray, Darren
name: Popat, Sanjay
name: Yousaf, Nadia
name: Jhanji, Shaman
name: Tatham, Kate
name: Cunningham, David
name: Van As, Nicholas
name: Young, Kate
name: Furness, Andrew JS
name: Pickering, Lisa
name: Beale, Rupert
name: Swanton, Charles
name: Gandhi, Sonia
name: Gamblin, Steve
name: Bauer, David LV
name: Kassiotis, George
name: Howell, Michael
name: Nicholson, Emma
name: Walker, Susanna
name: Wilkinson, Robert J
name: Larkin, James
name: Turajlic, Samra
Publisher: name: The Francis Crick Institute
Year: 2022
Subjects: subject: Neurosciences
subject: FOS: Clinical medicine
subject: Model organisms
subject: Biochemistry &amp; Proteomics
subject: Tumour Biology
subject: Signalling &amp; Oncogenes
subject: Genetics &amp; Genomics
subject: Developmental Biology
subject: Genome Integrity &amp; Repair
subject: Human Biology &amp; Physiology
subject: Structural Biology &amp; Biophysics
subject: Cell Biology
subject: Cell Cycle &amp; Chromosomes
subject: Stem Cells
subject: Chemical Biology &amp; High Throughput
subject: Infectious Disease
subject: Ecology,Evolution &amp; Ethology
subject: Immunology
subject: Metabolism
subject: Computational &amp; Systems Biology

description: Patients with blood cancer continue to have a greater risk of inadequate immune responses following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the context of the CAPTURE study (NCT03226886) we report immune responses in 80 patients with blood cancer who received a fourth dose of BNT162b2. We measured neutralising antibody titres (NAbT) using a live virus microneutralization assay against wild-type (WT), Delta, Omicron BA.1 and BA.2 and T cell responses against WT and Omicron BA.1 using an activation-induced marker (AIM) assay. The proportion of patients with detectable NAb titres and T cell responses after the fourth vaccine dose increases compared to those after the third vaccine dose. Patients who received B cell-depleting therapies within 12 months before vaccination have the greatest risk of not having detectable NAbT. In addition, we report immune responses in 57 patients with breakthrough infections after vaccination.